ESMO Breast 2020 | LILAC: comparing cardiac safety of ABP 980 with trastuzumab

Name: LILAC: comparing cardiac safety of ABP 980 with trastuzumab
Uploaded: 2020-05-13T00:00:00Z
Duration: 2 min 43 s
Description: Hans-Christian Kolberg, MD, PhD, of Marienhospital Bottrop, Bottrop, Germany, discusses LILAC, a randomized, double-blind, active-controlled study (NCT01901146) investigating the cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2+ early breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Hans-Christian Kolberg • 13 May 2020

ESMO Breast 2020

Breast Cancer ABP 980 Antibodies Trastuzumab

LILAC

Hans-Christian Kolberg, MD, PhD, of Marienhospital Bottrop, Bottrop, Germany, discusses LILAC, a randomized, double-blind, active-controlled study (NCT01901146) investigating the cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2+ early breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).